|1.||Ferrari, Livia: 1 article (02/2003)|
|2.||Braggio, Simone: 1 article (02/2003)|
|3.||Iavarone, Laura: 1 article (02/2003)|
|4.||Di Modugno, Enza: 1 article (02/2003)|
02/01/2003 - "In addition, in order to compare the therapeutic efficacy of GV143253A to that of vancomycin in a thigh infection caused by MRSA in immunocompetent mice, suitable dosing regimens were designed on the basis of previous pharmacokinetic-pharmacodynamic findings for GV143253A and on the human pharmacokinetic profile of the glycopeptide. "
02/01/2003 - "The results suggest that if the time of exposure to the pathogen above the MIC is at least 30% of the dosing interval, GV143253A could have a role in the clinical treatment of infections caused by MRSA, which is difficult to eradicate with current antibiotics."
|2.||Anti-Bacterial Agents (Antibiotics)